NCT05844956已完成1 期
A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Dizal Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2022年6月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).
研究概览
简要总结
This study is designed to evaluate the safety, tolerability, pharmacokinetic profile, and antitumor efficacy of DZD8586 in participants with relapsed or refractory B-NHL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All participants must provide a signed and dated written informed consent form prior to any study-specific procedures, sampling, and analysis.
- •Male and female participants must be ≥ 18 years of age when signing the informed consent form.
- •ECOG performance status score of 0 - 2 points and no disease deterioration in the past two weeks.
- •Participants with relapsed or refractory B-NHL must be cytologically or histologically confirmed.
- •Adequate bone marrow reserve (no blood transfusion within 7 days of the pre-enrollment visit, and no use of any stimulating factor or erythropoietin) and organ function.
- •Participants should be able to follow the requirements of this study for medication use and follow-up.
- •Female spouses (partners) of male participants who may become pregnant should use barrier contraception (such as condoms) during the participants' participation in the trial and within 6 months after the end of dosing. Male participants should also refrain from donating sperms during participation in the trial and within 6 months after the end of dosing.
- •Female participants should use adequate contraception such as abstinence, tubal ligation, use of hormonal contraception with a known lower risk of drug-drug interaction [levonorgestrel intrauterine device (Mirena), medroxyprogesterone injection (Depo Provera)], copper-containing intrauterine device, and partner's vasectomy during the trial and within 3 months after the end of the trial.
排除标准
- •Have unresolved adverse drug reactions (except for alopecia) of higher than grade 1 (as defined by CTCAE v5.0) before the start of dosing in the study.
- •A history of anticancer treatment within washout period as defined in the protocol.
- •Participants with B-NHL other than CNSL who have central nervous system or intraocular lymphoma lesions.
- •Participants with CNSL who have the following health conditions:
- •Unable to cooperate with a lumbar puncture or cerebrospinal fluid test.
- •Involvement of sites outside the CNS requiring systemic therapy.
- •Participants with condition requiring systemic glucocorticoid therapy at a dose of > 8 mg/day (dexamethasone equivalent dose); or participants requiring immunosuppressant or biologic therapy.
- •Active infectious diseases, including HBC, HCV, HIV, TB, etc.
- •Abnormal heart and lung function.
- •Refractory nausea and vomiting not well controlled by supportive care, chronic gastrointestinal disease, dysphagia, or previous surgical resection of bowel segments that may interfere with adequate drug absorption.
- •Participants diagnosed with other malignancies apart from B-cell lymphoma within the past 5 years. However, participants may also be enrolled if the current evidence shows that the participant has been clinically cured and the investigator believes that the potential benefit of treatment with DZD8586 outweighs the potential risk.
- •Participants with hypersensitivity to DZD8586 pharmaceutical excipients or other chemical analogs.
- •Participants with serious or poorly controlled systemic diseases as judged by the investigator or other evidence, including poorly controlled hypertension and active bleeding disorders.
- •Personnel involved in the planning and implementation of this study (only applicable to employees of the sponsor and study site).
- •Female participants who are breastfeeding or pregnant.
- •Participants who have taken DZD
- •Participants should not participate in the study if they are considered by the investigator to be unlikely to comply with study procedures, restrictions, and requirements.
研究组 & 干预措施
DZD8586
Experimental
干预措施: DZD8586 (Drug)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).
时间窗: 30 days after the last dose, assessed up to 2 years
次要结局
- Plasma and cerebral spinal fluid concentrations of DZD8586(Through cycle 0 day 1 (8 days for Cycle 0, 28 days for Cycle 1, then 21 days for each subsequent cycle, up to Cycle 4))
- Objective Response Rate(Through cycle 3 day 1 for non-CNSL or Cycle 1 day 15 for CNSL(21 days for each subsequent cycle, assessed up to 2 years))
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Study of AK119 Combined With AK104 in Patients With Advanced Solid TumorsSolid Tumor, AdultNCT05559541Akeso33
终止
1 期
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing CancersSquamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell LungAdvanced Solid TumorRefractory TumorMetastatic TumorColorectal NeoplasmsNCT05099549NKGen Biotech, Inc.11
招募中
1 期
A Study of AK131 in Patients With Advanced Solid TumorsSolid TumorNCT06166888Akeso130
撤回
1 期
NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung DiseaseLung DiseasePulmonary DiseaseAlpha-1 Antitrypsin Deficiency-associated Lung DiseaseAATDAlpha-1 Antitrypsin DeficiencyNCT06622668Intellia Therapeutics30
已完成
1 期
A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced MalignanciesAdvanced MalignancyNCT02978482AstraZeneca26